IL-23 p19

Assets acting on this target.

Class
IL-23 inhibitor
Pathway
IL-23 / Th17

IL-23 is a cytokine built from two protein subunits, p19 and p40, that together bind a receptor complex present on T helper 17 (Th17) cells and related innate immune cells. This signal sustains Th17 cells and drives their production of inflammatory messengers, notably interleukin-17 and interleukin-22, in a pathway referred to as IL-23/Th17. Overactivity of this axis contributes to chronic tissue inflammation seen in psoriasis, psoriatic arthritis, and inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Because p19 is unique to IL-23, antibodies engineered to bind p19 neutralize IL-23 specifically, in contrast to agents that target the shared p40 subunit, which also blocks interleukin-12, a related cytokine with distinct immune functions. The rationale for p19-selective inhibition is to interrupt the Th17-driven inflammatory cycle at its source while sparing pathways not implicated in the disease, aiming for durable control of inflammation across skin, joints, and intestinal tissue. Some newer molecules combine IL-23 blockade with inhibition of other inflammatory mediators, such as TNF-alpha or TL1A, reflecting efforts to address overlapping inflammatory pathways in cases where IL-23 alone does not account for the full disease process.

By indication

IL-23 p19 drugs compared

13 drugs, stage by indication
13 drugs acting on IL-23 p19: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
guselkumabTremfyaJohnson & Johnsonmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Ulcerative Colitis
mirikizumabOmvohEli Lillymonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Ulcerative Colitis
risankizumabSkyriziAbbVie, Boehringer Ingelheimmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Ulcerative Colitis
tildrakizumabIlumyaAlmirall, China Medical System, Sun Pharmaceutical Industriesmonoclonal antibodyApprovedApproved in Psoriasis; Approved in Psoriatic Arthritis
HS-20137Hansoh Pharmaceutical Group, Qyuns Therapeuticsmonoclonal antibodyPhase 3Phase 3 in Psoriasis
JNJ-78934804Johnson & JohnsonCo-antibody combination (guselkumab + golimumab, SC)Phase 3Phase 3 in Crohn's Disease; Phase 3 in Ulcerative Colitis
picankibartInnovent Biologicsmonoclonal antibody (anti-IL-23p19)Phase 3Phase 3 in Psoriasis; Phase 2 in Ulcerative Colitis
QL2106Qilu Pharmaceuticalmonoclonal antibodyPhase 3Phase 3 in Psoriasis
AvrukibartOruka Therapeuticsmonoclonal antibodyPhase 2Phase 2 in Psoriasis
SHR-1139Jiangsu Hengrui Pharmaceuticalsmonoclonal antibody (dual IL-23p19/IL-36R)Phase 2Phase 2 in Psoriasis; Phase 2 in Ulcerative Colitis
SPY003Spyre Therapeuticsmonoclonal antibody (anti-IL-23)Phase 2Phase 2 in Ulcerative Colitis
SOR102Sorriso PharmaceuticalsBiologic (oral dual TNFα/IL-23(p19) inhibitor)Phase 1Phase 1 in Ulcerative Colitis
TL-003Bionyra Pharma, TrueLab Biopharmaceuticalbispecific antibody (anti-TL1A/IL-23, extended half-life)Phase 1Phase 1 in Ulcerative Colitis

← all mechanisms